AstraZeneca Acquires Thrombosis Drug CandidateBy
AstraZeneca has entered into an agreement with APT Therapeutics, a privately held biopharmaceutical company headquartered in St. Louis, Missouri, to acquire APT Therapeutic’s thrombosis drug candidate, APT102, a human apyrase therapy.
Under the agreement, AstraZeneca will make an upfront undisclosed cash payment to APT. APT will be eligible to receive future payments upon achievement of certain key development milestones. AstraZeneca will fund all future clinical trials for heart attack and/or stroke.
Source: APT Therapeutics